---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-214362"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:49:27.918522+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics prices $70M underwritten offering of 7.8M shares at $9.00

## Summary
- Underwritten offering of 7,777,778 shares at $9.00/share, gross proceeds ~$70M.
- Investors include RA Capital, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital, Avidity Partners, Janus Henderson, Surveyor Capital.
- Expected close on Aug 18, 2023; Cowen, Leerink, Evercore as book-runners.
- Offering priced at premium to closing price; sold under effective shelf registration statement.

## SEC filing metadata
- accession: 0001193125-23-214362
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312523214362/0001193125-23-214362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312523214362/d510715d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-214362
- JSON: https://secwatch.observer/filing/0001193125-23-214362.json
- Plain text: https://secwatch.observer/filing/0001193125-23-214362.txt

## Key facts
- Material Agreements
  AN2 Therapeutics, Inc. entered into Underwriting Agreement with Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named in Schedule A therein valued at approximately $70.0 million (effective 2023-08-15).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named in Schedule A therein
  - Value: approximately $70.0 million
  - Effective: 2023-08-15
  source text: On August 15, 2023, AN2 Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named in Schedule A therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of 7,777,778 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $9.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312523214362/0001193125-23-214362-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.